PARIS--(BUSINESS WIRE)--Regulatory News:
BioAlliance Pharma SA (Paris:BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €332,000 for the quarter of 2011 and announced progress for Loramyc® commercialization in Italy.
BioAlliance Pharma SA (Paris:BIO), a company dedicated to specialty and orphan oncology products, today reported a consolidated turnover of €332,000 for the quarter of 2011 and announced progress for Loramyc® commercialization in Italy.
